MULTIPRED2

MULTIPRED2 predicts peptide–HLA binding across HLA Class I and II alleles and supertypes to identify promiscuous T-cell epitopes and assess population coverage for immunological and vaccine research.

Key Features:

• Broad Allelic Coverage: Supports prediction of peptide binding for individual HLA alleles, combinations of alleles, and HLA supertypes, including 13 HLA Class I supertypes (A1, A2, A3, A24, B7, B8, B27, B44, B58, B62, C1, and C4) and 13 HLA Class II DR supertypes (DR1, DR3, DR4, DR6, DR7, DR8, DR9, DR11, DR12, DR13, DR14, DR15, and DR16), covering 1077 variants representing these 26 supertypes.
• Visualization Modules: Maps promiscuous T-cell epitopes and regions of high target concentration (T-cell epitope hotspots) using graphic representations that display predicted binding peptides and immunological hotspots, including global heat-map views.
• Population Coverage Calculation: Calculates population coverage for peptide binding predictions across five major demographic groups in North America.

Scientific Applications:

• T-cell Epitope Identification: Complements experimental methods by predicting peptide–HLA binding to support identification of T-cell epitopes.
• Vaccine Development: Informs vaccine design by identifying promiscuous epitopes, immunological hotspots, and population coverage across North American demographic groups.
• Personalized Medicine and Therapeutic Discovery: Supports personalized immunology and discovery of novel therapeutic epitopes by predicting peptide binding across diverse HLA molecules.

Methodology:

Integrates NetMHCpan and NetMHCIIpan algorithms to predict peptide–HLA interactions.